REG - MicroSalt PLC - Exercise of Warrants and Total Voting Rights

MicroSaltAnnouncement

21/02/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240221:nRSU9824Da&default-theme=true

RNS Number : 9824D  MicroSalt PLC  21 February 2024

21 February 2024

MicroSalt Plc

("MicroSalt" or the "Company")

 

Exercise of Warrants and Total Voting Rights

 

MicroSalt plc, a company commercialising a patented technology to produce
full-flavour, low-sodium salt for food manufacturers and consumers, announces
that certain shareholders have exercised their warrants over 100,001 ordinary
shares of £0.001625 each ("Ordinary Shares"), which were granted on admission
to AIM. They have been exercised at a price of 47.3p per Ordinary Share, for
an aggregate value of £47,300. Further details on these warrants are
contained in the Admission Document on the Company's website www.microsalt.co
(http://www.microsalt.co) . As at today's date, 7,213,975 warrants remain
outstanding.

 

Application has been made to the London Stock Exchange for the admission of
100,001 new Ordinary Shares. It is expected that admission will become
effective on or around 22 February 2024.

 

Following admission, the total number of ordinary shares and voting rights in
the Company will be 43,217,154. The Company does not hold any shares in
treasury.

 

The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.

 

For further information, please visit MicroSalt's website
(https://microsaltinc.com/home-uk/) or contact:

 

 MicroSalt plc                                            Via Flagstaff PR
 Rick Guiney, CEO

 Zeus (Nominated Adviser and Broker)                      +44 (0)20 3829 5000
 David Foreman / James Edis (Investment Banking)
 Dom King (Corporate Broking), Rupert Woolfenden (Sales)

 Flagstaff PR (Financial PR/IR)                           +44 (0)20 7129 1474
 Tim Thompson / Alison Allfrey / Anna Probert

 

 

Notes to Editors

 

MicroSalt® produces a patented full-flavour, low-sodium salt for food
manufacturers and consumers.

 

MicroSalt is a major potential disruptor in the food market, thanks to its
micron sized particles which deliver the same sense of saltiness to a wide
range of foods but with approximately 50% less sodium. Excess sodium
consumption is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier alternatives to
traditional salt. The WHO has set a target for reducing global sodium intake
by 30% by 2025, which it estimates will save 7 million lives by 2030.

 

Each year, cardiovascular disease costs the UK £19 billion - if the average
salt intake was reduced by one gram per day, it has been estimated that 4,147
lives and £288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70 per cent. of the
typical person's sodium intake is hidden in processed foods.

 

Operational since 2018, MicroSalt uses a patent-protected technology which
helps create high barriers to entry within the reduced-sodium salt market. The
group has a US patent and 14 patent applications pending in other
jurisdictions globally.

 

The Directors believe that MicroSalt is well positioned to capture growth in
the low sodium market, which is expected to grow exponentially, and that there
is also scope to enter the larger salt market.

 

MicroSalt has a three-pronged marketing strategy, targeting large B2B food
manufacturers, the B2C market and e-commerce customers. Microsalt's all
natural, low-sodium solution is well positioned to take advantage of the
fast-growing market for a healthier alternative to traditional salt.

 

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPPUGAPUPCGCG